Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Clinical chemistry. pii: clinchem.2016.257212. doi: 10.1373/clinchem.2016.257212
    GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes.
    Pavo N1,  Wurm R2,  Neuhold S3,  Adlbrecht C4,  Vila G5,  Strunk G6,  Clodi M7,  Resl M8,  Brath H9,  Prager R10,  Luger A11,  Pacher R12,  Hülsmann M13
    Author information
    1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
    2Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
    3Department of Anesthesia, Division of Cardio-Thoracic-Vascular Anesthesia and Intensive Care Medicine, Medical University of Vienna, Vienna, Austria.
    4Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
    5Department of Internal Medicine III, Division of Endocrinology, Medical University of Vienna, Vienna, Austria.
    6Technical University Dortmund, Dortmund, Germany; FH Campus Vienna, Vienna, Austria and Complexity Research, Vienna, Austria.
    7Department of Internal Medicine, Hospital Barmherzige Brüder Linz, Linz, Austria.
    8Department of Internal Medicine, Hospital Barmherzige Brüder Linz, Linz, Austria.
    9Health Center South, Diabetes Outpatient Clinic, Vienna, Austria.
    10Department of Medicine III, Hospital Hietzing, Vienna, Austria.
    11Department of Internal Medicine III, Division of Endocrinology, Medical University of Vienna, Vienna, Austria.
    12Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
    13Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria; martin.huelsmann@meduniwien.ac.at.
    Abstract

    BACKGROUND: Diabetes has been linked epidemiologically to increased cancer incidence and mortality. Growth differentiation factor 15 (GDF-15) is increased in patients with diabetes and has recently been linked to the occurrence of cancer. We investigated whether circulating GDF-15 concentrations can predict the incidence of malignant diseases in a diabetic patient cohort already facing increased risk for cancer.

    METHODS: We prospectively enrolled a total of 919 patients with type 2 diabetes and no history of malignant disease, who were clinically followed up for 60 months. GDF-15, N-terminal pro-B-type natriuretic peptide and troponin T were measured at baseline; an additional 4 cardiovascular biomarkers were determined for a subpopulation (n = 259). Study end point was defined as the first diagnosis of any type of cancer during the follow-up period.

    RESULTS: During a median follow-up of 60 months, 66 patients (7.2%) were diagnosed with cancer. Baseline circulating GDF-15 concentrations were higher in patients that developed cancer over the follow-up period when compared to cancer-free patients. Increased GDF-15 concentrations were significantly associated with cancer incidence [crude hazard ratio (HR) per 1-IQR (interquartile range) increase 2.13, 95% CI 1.53-2.97, P < 0.001]. This effect persisted after multivariate adjustment with an adjusted HR of 1.86 (95% CI 1.22-2.84; P = 0.004). Among the 4 additionally tested cardiovascular markers in the subpopulation, only troponin T and C-terminal proendothelin-1 showed a significant association with future cancer incidence with unadjusted HRs of 1.71 (95% CI 1.28-2.28, P < 0.001) and 1.68 (95% CI 1.02-2.76, P = 0.042), respectively.

    CONCLUSIONS: Increased circulating concentrations of GDF-15 are associated with increased cancer incidence in patients with type 2 diabetes.


    © 2016 American Association for Clinical Chemistry.

    Publikations ID: 27756762
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt